Common variants of Drosophila melanogaster Cyp6d2 cause camptothecin sensitivity and synergize with loss of Brca2

• Published in: G3 : genes - genomes - genetics Vol. 3; no. 1; pp. 91 - 99
• Main Authors: Thomas, Adam M, Hui, Carrie, South, Adam, McVey, Mitch
• Format: Journal Article
• Language: English
• Published: United States Genetics Society of America 01.01.2013
• Subjects: Animals; BRCA2 Protein - genetics; Camptothecin - analogs & derivatives; Camptothecin - pharmacology; Cytochrome P-450 Enzyme System - genetics; Cytochrome P-450 Enzyme System - metabolism; DNA Damage - genetics; DNA Primers - genetics; DNA Repair - drug effects; Drosophila melanogaster - genetics; Drosophila Proteins - genetics; Drosophila Proteins - metabolism; Drug Evaluation, Preclinical - methods; Genetic Complementation Test; Insect Proteins - genetics; Investigations; Irinotecan; Polymorphism, Genetic - genetics; Reverse Transcriptase Polymerase Chain Reaction; Topoisomerase I Inhibitors - pharmacology; Topotecan - pharmacology; cytochrome p450; homologous recombination; double-strand breaks; chemotherapeutics

Many chemotherapeutic agents selectively target rapidly dividing cells, including cancer cells, by causing DNA damage that leads to genome instability and cell death. We used Drosophila melanogaster to study how mutations in key DNA repair genes affect an organism's response to chemotherapeutic...